RSWM
VNDA icon

Robertson Stephens Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Robertson Stephens Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,000
Closed -$159K – 676
2025
Q4 		$159K Buy
+18,000
New +$99.1K ﹤0.01% 613

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Robertson Stephens Wealth Management's VNDA Position: Q1 2026 in Review

Robertson Stephens Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2026, closing a stake of 600 shares — an estimated $5.29K sold.

Robertson Stephens Wealth Management first reported a position in VNDA in Q4 2025 and held it in 1 quarter. The position peaked at $5.29K in Q4 2025. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Robertson Stephens Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Robertson Stephens Wealth Management sold 600 Vanda Pharmaceuticals shares in Q1 2026, an estimated $5.29K.
  • Robertson Stephens Wealth Management first reported a position in Vanda Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Robertson Stephens Wealth Management's Vanda Pharmaceuticals position peaked at $5.29K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q1 2026, filed 28 Apr 2026.